74 related articles for article (PubMed ID: 19550127)
1. Insulin resistance in patients with advanced prostate cancer undergoing intermittent or continuous androgen blockade.
Chen W; Yu ZX; Xie H; Deng ZX; Zhang FY; Chen SY; Weng ZL
Ai Zheng; 2009 Feb; 28(2):150-3. PubMed ID: 19550127
[TBL] [Abstract][Full Text] [Related]
2. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
[TBL] [Abstract][Full Text] [Related]
3. [Serum leptin and insulin resistance in obesity and effects of sibutramine on them].
Wu J; Lei MX; Chen HL
Hunan Yi Ke Da Xue Xue Bao; 2003 Dec; 28(6):605-7. PubMed ID: 15804071
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome].
Liu ZA; Xue YM; Chen LX; Cai Q; Chen H; Zhang J; Cui QH; Ge J; Yuan T
Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):586-90. PubMed ID: 15498183
[TBL] [Abstract][Full Text] [Related]
6. Effect of surgical castration on risk factors for arteriosclerosis of patients with prostate cancer.
Xu T; Wang X; Hou S; Zhu J; Zhang X; Huang X
Chin Med J (Engl); 2002 Sep; 115(9):1336-40. PubMed ID: 12411107
[TBL] [Abstract][Full Text] [Related]
7. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
8. Intermittent androgen blockade or continuous androgen blockade in advanced prostate cancer: a meta-analysis of efficacy, quality of life and side effects.
Zhu J; Wang Y; Xu S; Sun Z
J BUON; 2012; 17(2):350-6. PubMed ID: 22740217
[TBL] [Abstract][Full Text] [Related]
9. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
Efstathiou JA; Chen MH; Renshaw AA; Loffredo MJ; D'Amico AV
Cancer; 2007 Apr; 109(8):1493-8. PubMed ID: 17340594
[TBL] [Abstract][Full Text] [Related]
10. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T
J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
[TBL] [Abstract][Full Text] [Related]
12. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
13. [Effects of insulin receptor substrate-1 and its serine phosphorylation and tyrosine phosphorylation on insulin resistance in skeletal muscle cells in the state of sepsis: experiment with rats].
Yan XW; Li WQ; Wang XD; Li JS; Li N
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(41):2922-7. PubMed ID: 17288791
[TBL] [Abstract][Full Text] [Related]
14. Relationship between hyperinsulinemia and ambulatory blood pressure monitoring of lean and overweight male hypertensives.
Feldstein CA; Renauld A; Akopian M; Olivieri AO; Garrido D
J Cardiovasc Risk; 1998 Feb; 5(1):25-30. PubMed ID: 9816552
[TBL] [Abstract][Full Text] [Related]
15. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
17. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
Pether M; Goldenberg SL; Bhagirath K; Gleave M
Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
[TBL] [Abstract][Full Text] [Related]
18. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
[TBL] [Abstract][Full Text] [Related]
19. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
20. [The changes in insulin sensitivity under stress and its clinical significance in the critically ill patients].
Cao FT; Zheng ZQ
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2008 Aug; 20(8):482-5. PubMed ID: 18687177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
